Icotrokinra Beats Deucravacitinib in Psoriasis Trial
- Okay, here's a breakdown of teh references provided, formatted for easier use.
- note: The dates (September 15, 2025 and October 6, 2025) are in the future as of today, november 21, 2023.This suggests the text is from a future publication...
Okay, here’s a breakdown of teh references provided, formatted for easier use. I’ve extracted the key details from each citation:
References
- Study Title: A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderate-to-Severe Plaque Psoriasis.
* ClinicalTrials.gov identifier: NCT06220604
* Last Updated: September 15, 2025
* Accessed: October 6, 2025
* Link: https://clinicaltrials.gov/study/NCT06220604
- Study Title: A study of JNJ-7724113 in adolescent and adult participants with moderate to severe plaque psoriasis (ICONIC-LEAD).
* ClinicalTrials.gov Identifier: NCT06095115
* Last Updated: September 15, 2025
* Accessed: October 6, 2025
* Link: https://clinicaltrials.gov/study/NCT06095115
- Article: Halpern L. icotrokinra demonstrates meaningful skin clearance in moderate-to-severe plaque psoriasis.
* Journal: Pharmacy Times
* Published: March 10, 2025
* Accessed: October 6, 2025
* Link: https://www.pharmacytimes.com/view/icotrokinra-demonstrates-meaningful-skin-clearance-in-moderate-to-severe-plaque-psoriasis
- Article: Halpern L.Icotrokinra demonstrates meaningful skin clearance in arduous-to-treat scalp… (The citation is incomplete, but the beginning is provided.)
note: The dates (September 15, 2025 and October 6, 2025) are in the future as of today, november 21, 2023.This suggests the text is from a future publication or a draft.